Qualifications and Employment History
- BA in Natural Sciences (Part II Genetics), University of Cambridge, 1992.
- Postdoctoral work at London Research Institute, Cancer Research UK, 1996-1999.
- Joined Imperial College in 1999 as Lecturer and head of the Androgen Signalling Group in the Department of Oncology.
- Current position: Professor of Cancer Biology, Non-Clinical Head of Prostate Cancer Research in Department of Surgery & Cancer.
- Mechanisms of androgen receptor action.
- Androgen signalling in development and disease.
- Nuclear receptor coactivators and corepressors.
- Mechanisms of therapy resistance in hormone-dependent cancers.
- Novel therapies for prostate cancer.
- Discovery and validation of biomarkers for prostate cancer.
- Role of microRNAs in androgen signalling.
- BSc Medical Biosciences - Module Lead for Cancer Biology
- Lecturer and project supervisor for MBBS BSc year
Postgraduate Taught Courses
- MSc Molecular Medicine
- MRes Cancer Biology
- MSc Human Reproduction
- PhD project supervisor
- Masters project supervisor for MRes Cancer Biology, MSc Human Reproduction, MRes Biomedical Sciences, MSc Molecular Medicine
Other College roles
Member of the Imperial College 3Rs committee
Member of the Postgraduate Education Committee for Surgery & Cancer
Member of the Academic Opportunities Committee for Surgery & Cancer
Member of the Imperial Student Withdrawals/Appeal panel
Collaborators and External Committees
Please see "Research" tab above
et al., 2017, A novel role for GSK3β as a modulator of Drosha microprocessor activity and MicroRNA biogenesis, Nucleic Acid Research, Vol:45, ISSN:2159-3345, Pages:2809-2828
Bevan C, 2016, Women in cancer profile: A gender agenda?, Endocrine-related Cancer, Vol:23, ISSN:1479-6821, Pages:P5-P8
Leach DA, Powell SM, Bevan C, 2016, New roles for nuclear receptors in prostate cancer, Endocrine-related Cancer, Vol:23, ISSN:1479-6821, Pages:T85-T108
et al., 2016, Amplification-free detection of circulating microRNA biomarkers from body fluids based on fluorogenic oligonucleotide-templated reaction between engineered peptide nucleic acid probes: application to prostate cancer diagnosis, Analytical Chemistry, Vol:88, ISSN:0003-2700, Pages:8091-8098
et al., 2014, Engineered repressors are potent inhibitors of androgen receptor activity, Oncotarget, Vol:5, ISSN:1949-2553, Pages:959-969
et al., 2013, Visualising Androgen Receptor Activity in Male and Female Mice, PLOS One, Vol:8, ISSN:1932-6203
et al., 2013, Circulating microRNAs as potential new biomarkers for prostate cancer, British Journal of Cancer, Vol:108, ISSN:1532-1827, Pages:1925-1930
et al., 2012, Androgen-regulated processing of the oncomir MiR-27a, which targets Prohibitin in prostate cancer, Human Molecular Genetics, Vol:21, ISSN:0964-6906, Pages:3112-3127
et al., 2011, FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth, Cancer Research, Vol:71, ISSN:0008-5472, Pages:914-924
Brooke GN, Parker MG, Bevan CL, 2008, Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression, Oncogene, Vol:27, ISSN:0950-9232, Pages:2941-2950
et al., 2007, Prohibitin, a protein downregulated by androgens, represses androgen receptor activity, Oncogene, Vol:26, ISSN:0950-9232, Pages:1757-1768